<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28531">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053116</url>
  </required_header>
  <id_info>
    <org_study_id>B1731006</org_study_id>
    <nct_id>NCT02053116</nct_id>
  </id_info>
  <brief_title>A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin</brief_title>
  <official_title>A 6-week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 Administered With Canagliflozin In Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a study to evaluate the effects of an investigational compound administered at 200
      mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2
      Diabetes Mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    On 25April2014, study was terminated before any dosing due to an AE of safety concern that
    occurred in protocol B1731003 with the same drug.
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo</measure>
    <time_frame>Week 0, 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo</measure>
    <time_frame>Weeks 0 and 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Weeks 0, 2, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting total cholesterol</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-peptide AUC(0-5) during mixed meal tolerance test (MMTT)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in homeostatic model assessment for Î²-cell function (HOMA B)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations for PF-05175157</measure>
    <time_frame>Weeks 2, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in body weight</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in high density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in triglycerides</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non-HDL cholesterol</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in very low density lipoprotein (VLDL)</measure>
    <time_frame>Weeks 0, 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PF-05175157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>Tablet, 200 mg, twice daily, 6 weeks</description>
    <arm_group_label>PF-05175157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, 0 mg, twice daily, 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type 2 Diabetes Mellitus  and treated with metformin at a dose greater
             than or equal to 1000 mg for at least 3 months and are willing to switch to
             canagliflozin from metformin for the duration of the study

          -  Hemoglobin A1c of 7-10% at screening.

          -  Body Mass Index of at least 25 kg/m2.

        Exclusion Criteria:

          -  Compliant with study drug administration during the run-in period and throughout the
             trial.

          -  Patients with fasting triglycerides greater than 500 mg/dL at screening.

          -  History of certain diabetic complications or cardiac problems.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731006&amp;StudyName=A%206-Week%20Study%20To%20Determine%20The%20Safety%20And%20Effect%20Of%20An%20Investigational%20Drug%20Given%20With%20Canagliflozin%20In%20Adults%20With%20Type%202%20Diabetes</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
